Corcept Therapeutics Inc expected to post earnings of 23 cents a share - Earnings Preview

Corcept Therapeutics Incorporated

26/07/2024 22:24

* Corcept Therapeutics Inc  CORT.OQ   CORT.O  is expected
to show
a rise in quarterly revenue when it reports  results on July 29
for the period ending June 30 2024
    * The Menlo Park California-based  company is expected to
report a
31.9% increase in revenue to $155.226 million from $117.72
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Corcept Therapeutics Inc
is
for earnings of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corcept
Therapeutics Inc is $40.00​, above​ its last closing price
of $34.87. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.27        0.22       0.25      Beat    13.6
 Dec. 31 2024  0.27        0.26       0.28      Beat    8.5
 Sep. 30 2023  0.23        0.22       0.28      Beat    28.2​
 Jun. 30 2023  0.15        0.15       0.25      Beat    66.7
 ​​Mar.        0.19        0.19       0.14      Missed  -27.6
 31 2023                                                
 Dec. 31 2022  0.23        0.23       0.14      Missed  -37.8​
 Sep. 30 2022  0.22        0.23       0.30      Beat    33.3
 Jan. 1 0001   0.23        0.24       0.24      Met     2.1
 This summary was machine generated July 26 at 21:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)